Brucellosis is an important public health problem in Peru. We evaluated 48 human Brucella melitensis biotype 1 strains from Peru between 2000 and 2006. MICs of isolates to doxycycline, azithromycin, gentamicin, rifampin, cipruftoxacin, and tl'imethoprim-sulfamethoxazole were determined by the Etest method. All isulates were sensitive to tested drugs during the periuds of testing. Relapses did nut appear to be related tu drug resistance.
Infection by Brucella species is a major cause of zoonotic disease. Brucellosis is endemic in the Mediterranean littoral, southwest and central Asia, the Indian subcontinent, and Latin America (12) . ln Peru, approximately 1,000 cases of human brucellosis ( overw·helmingly due to B. melitensis) are reported per year; up tc1 25';{. of these cases arc identified in Callao, the pun city of the capital, Lima ( 11 ) . Infection in Peru typically results from the consumption of unpasteurized dairy products or, less commonly, from occupational exposure to the products of conception of infected mammals (13). Ongoing vaccination campaigns directed at preventing goat brucellosis may be reducing the number of human cases (10) .
Commonly recommended agents for the treatment of brucellosis include doxycycline (DOX), rifampin (RIF), streptomycin, gentamicin (GE), and trimethoprim-sulfarnethoxazole (SXT); generally, two or three drugs arc used in combination for 6 weeks or longer, depending on the location of infection and the associated clinical syndrome. Certain llumoquinoloncs (e.g., levotloxacin) and macrolides (e.g., azithromycin [AZM]) may have an adjunctive mle in the management of the disorder (2, 8, 14) .
Antimicrobial drug resistance in Brucella is unusual. Increases in the MICs of ceftriaxone and streptomycin have been reported in Turkey ( 15), although these agents remain active. Intermediate rifampin susceptibility elsewhere in Turkey has been described previously (1 ) . Limited in vitro susceptibility to rifampin and trimethoprim-sulfamethoxazole in Kuwait (5) and Mcxicu (9) has similarly been reported.
In this study, we sought to evaluate the susceptibility of Brucella melitensis from human clinical blood cultures in Lima and Callao, Pcm, w common antimicrobial drugs. We additionally wished to determine any changes in susceptibility during two distinct time periods in this area of endemic-ity. Lastly, we intended to examine whether Brucella isolates obtained from patients with relapsed disease differed in terms of susceptibility from specimens obtained during primary infectil111S.
(The data included in this paper were presented in part at the 110th General All cultures, species identification, and antimicrobial susceptibility tests were performed in the Bacteriology Laboratory of the Naval Medical Research Center Detachment (NMRCD) using the Ruiz-Castafieda and lysis centrifugation methods as previously described (3, 6, 7) . Drictly. suspected colonies were identified on Brucella agar supplememed with 5')1 sheep's blood and then evaluated based upon Gram stain appearance. growth characteristics, and biochemical testing. Specimens were confirmed by slide agglutination using anti-Brucella polyclonal serum. Further determination of species and biotype was conducted by testing C0 2 growth requirements. urease and H 2 S production, dye sensitivity using thioninc and basic fuchsin, and agglutination with monospecific antisera to A and M antigens.
Antimicrobial susceptibility testing on confirmed B. melitensis isolates was then conducted using the Etest method (AB hioMerieux, Solna, Sweden). Mean MTCs of DOX, AZM, GE, RIF, ciprofloxacin (CIP), and SXT were tested by inoculating a suspension of bacteria (adjusted to 0. plemented with 5% sheep's blood, followed by the application of Etest strips. MICs were then determined following 48 h of incubation.
The following reference strains were used fnr quality control during susceptibility testing: Escherichia coli 25922, Staphylococcus au reus 25923, Brucella abortus 2308, Brucella melitensis rev-I, and Bmcel/a canis RM6/66. All reference strains were obtained from the American Type Culture Collection. Manassas, VA. We interpreted MLC values according to the Clinical and Laboratory Standards Institute (CLSI) guidelines for slow-growing bacteria (Haemophilus spp.) as described elsewhere ( 4). Statistical significance was delermined by analysis of variance (ANOVA) using SPSS version 17.0 (SPSS Inc., Chicago, IL).
All 4R isolates were contirmcd as B. melitensis and agglutinated with an ti-M monospecific sera, consistent with biotype 1. Five of the 48 isolates were from patients with relapsed disease, while the remaining 43 were from primary infections. The MTC., 0 and MTCJtl values of tested antibiotics are shown in Table 1 . All isolates were generally susceptible to the tested agents. One isnlate had reduced susceptibility to RIF (MIC: (Table 1 ) . Although the changes in mean doxycycline. gentamicin, rifampin, and ciprotloxacin MICs between the two periods were statistically significant, the absolute differences were small and did not appear clinically meaningful.
Isolates from patients with relapsed disease were compared with primary specimens from the same patients when available. Three of five patients had primary specimens available. There were no observed differences in the antimicrobial susceptibilities of strains fwm patients with primary infection versus those from patients in relapse. No resistance was detected in the isolates from patients in relapse, and MIC values were generally low (Table 2) .
In summary, Brucella melitensis strains causing human disease with bacteremia in metropolitan Lima, Peru, are broadly susceptible to common antibiotics, with no new resistance noted in the periods of time studied. Relapse of clinical disease does not appear to he associated with antimicrobial drug resistance. These results, however, arc limited by a narrow geographic scope and relatively small numbers. The routine evaluation of drug susceptibility in Brual/a species is hampered by the lack of Brucella-specific CLSI guidelines, the need fm binsafety level 3 conditions during susceptibility testing, and the risk of laboratory staff exposure. Periodic testing of a subset of isolates in reference laboratories may be a more appropriate and safer means for monitoring Brucella drug susceptibility over broad regions. 
